Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Zammit

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Postgraduate Medicine|October 29, 2020
Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trialsMargaret Moline, Gary Zammit, Jane Yardley, et al.
Annals of Neurology|January 19, 2020
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderYves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
Eating Behaviors|September 20, 2016
Is night eating syndrome associated with obstructive sleep apnea, BMI, and depressed mood in patients from a sleep laboratory study?Allan Geliebter, Haley McOuatt, Cora B Tetreault, et al.
Sleep|April 2, 2017
Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled StudyThomas Roth, Jed Black, Raymond Cluydts, et al.
Journal of Clinical Psychopharmacology|August 28, 2014
Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep lossMaria Gasior, Jon Freeman, Gary Zammit, et al.
Journal of Clinical Psychopharmacology|September 3, 2014
A generalized estimating equation approach to analysis of maintenance of wakefulness testing in a study of lisdexamfetamine dimesylate, armodafinil, and placebo in sleep-deprived adultsThomas Roth, Jon Freeman, Gary Zammit, et al.
Journal of Psychiatric Practice|March 19, 2015
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agentSheldon Preskorn, Matthew Macaluso, D O Vishaal Mehra, et al.
Sleep|April 17, 2010
Nonrestorative sleep as a distinct component of insomniaThomas Roth, Gary Zammit, Alan Lankford, et al.
Sleep Medicine|November 1, 2003
A new questionnaire to detect sleep disordersThomas Roth, Gary Zammit, Clete Kushida, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 4, 2008
A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomniaMilton K Erman, Gary Zammit, Robert Rubens, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Postgraduate Medicine|October 29, 2020
Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trialsMargaret Moline, Gary Zammit, Jane Yardley, et al.
Annals of Neurology|January 19, 2020
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderYves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
Eating Behaviors|September 20, 2016
Is night eating syndrome associated with obstructive sleep apnea, BMI, and depressed mood in patients from a sleep laboratory study?Allan Geliebter, Haley McOuatt, Cora B Tetreault, et al.
Sleep|April 2, 2017
Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled StudyThomas Roth, Jed Black, Raymond Cluydts, et al.
Journal of Clinical Psychopharmacology|August 28, 2014
Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep lossMaria Gasior, Jon Freeman, Gary Zammit, et al.
Journal of Clinical Psychopharmacology|September 3, 2014
A generalized estimating equation approach to analysis of maintenance of wakefulness testing in a study of lisdexamfetamine dimesylate, armodafinil, and placebo in sleep-deprived adultsThomas Roth, Jon Freeman, Gary Zammit, et al.
Journal of Psychiatric Practice|March 19, 2015
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agentSheldon Preskorn, Matthew Macaluso, D O Vishaal Mehra, et al.
Sleep|April 17, 2010
Nonrestorative sleep as a distinct component of insomniaThomas Roth, Gary Zammit, Alan Lankford, et al.
Sleep Medicine|November 1, 2003
A new questionnaire to detect sleep disordersThomas Roth, Gary Zammit, Clete Kushida, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 4, 2008
A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomniaMilton K Erman, Gary Zammit, Robert Rubens, et al.
Pageof 6